osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
adaura os results from for adjuvant osimertinib for egfr mutated resected nsclc showing 5 year os rate of 85 vs 73%, hr 0.49 #asco23 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.